GAITHERSBURG, Md., Nov. 2, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to the development and commercialization of next-generation vaccines for serious infectious diseases, today announced the appointment of Richard Rodgers, MBA on your board as an independent director. Rodgers brings extensive biopharmaceutical management experience to his position on the Novavax Board of Directors.
"Rick's deep experience in the pharmaceutical industry, coupled with his keen insights in building fast-growing companies and financial leadership, will be invaluable as we continue to commercialize our COVID-19 vaccine and expand our pipeline." of vaccines," said Stanley C. Erck, President and CEO of Novavax.
From 2010 to 2013, Rodgers was the co-founder, executive vice president, chief financial officer, secretary and treasurer of TESARO, Inc., a biopharmaceutical company that was acquired in January 2019 by GSK for more than $5 billion. From 2009 to 2010, Rodgers served as CFO and Senior Vice President of Abraxis BioScience, Inc., a biotechnology company that was acquired by Celgene for $2.9 billion. From 2004 to 2008, Rodgers served as Senior Vice President, Controller and Chief Accounting Officer for MGI PHARMA, Inc., a biopharmaceutical company that was acquired in January 2008 by Eisai for $3.9 billion.
Rodgers is a member of the boards of directors and chairman of the audit committee and a member of the compensation committee of Ocuphire Pharma, Inc., Sagimet Biosciences, Inc. and Ardelyx, Inc.
"This is a very exciting time to join the Novavax Board," said Rodgers. "I look forward to working with my fellow directors to support Novavax as it brings its first approved vaccine to market on a global scale and continues its growth into new vaccine areas."
Rodgers has a Bachelor of Science in Financial Accounting from St. Cloud State University and a Master of Business Administration in Finance from the University of Minnesota Carlson School of Business.
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that advances global health through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent health needs around the world. Novavax's COVID-19 vaccine, NVX-CoV2373, has received approval from multiple regulatory authorities around the world, including the US FDA, the European Commission and the World Health Organization. The vaccine is under review by multiple regulatory agencies around the world, including for additional indications and populations such as adolescents and as a booster. In addition to its COVID-19 vaccine, Novavax is also currently evaluating a combined seasonal flu-COVID vaccine candidate in a Phase 1/2 clinical trial, combining NVX-CoV2373 and NanoFlu*, its quadrivalent vaccine candidate. against influenza under investigation, and is also evaluating a vaccine based on the Omicron strain (NVX-CoV2515), as well as a bivalent vaccine based on the Omicron/original strain. These candidate vaccines incorporate Novavax's proprietary saponin-based adjuvant Matrix-M to enhance the immune response and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and contact us on LinkedIn.
Statements in this document relating to the future of Novavax, its operational plans and prospects, the timing of clinical trial results, the continued development of NVX-CoV2373, NVX-CoV2515, a bivalent vaccine candidate, an investigational vaccine candidate against quadrivalent influenza and a COVID-19 investigational combined influenza vaccine candidate, the scope, timing, and outcome of future submissions and regulatory actions, additional worldwide authorizations of NVX-CoV2373 for use in adults and adolescents, and as reinforcement, the evolution of the COVID-19 pandemic, the potential impact and scope of Novavax and NVX-CoV2373 to address vaccine access, control the pandemic and protect populations, efficacy, safety, the anticipated use and expected delivery of NVX-CoV2373 and other Novavax vaccine candidates are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, challenges in satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy regulatory authorities. applicable regulations; unforeseen challenges or delays in conducting clinical trials; difficulty obtaining scarce raw materials and supplies; resource limitations, including human capital and manufacturing capacity, on Novavax's ability to follow planned regulatory pathways; challenges in meeting contractual requirements under agreements with multiple commercial, government and other entities; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax's Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). Investors are cautioned not to place undue reliance on the forward-looking statements contained in this press release. We encourage you to read our SEC filings, available at www.sec.gov and www.novavax.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we do not undertake any obligation to update or revise any of the statements. Our business is subject to material risks and uncertainties, including those listed above. Investors, potential investors and others should carefully consider these risks and uncertainties.
Contacts:InvestorsErika Schultz | firstname.lastname@example.org
MediosAli Chartan by Giovanna Chandler | email@example.com
logo - link
View original content: enlace